Actuate Therapeutics awards warrants for 3M shares
The warrants have a $0.5325 exercise price and may be exercised from October 28, 2026, through October 28, 2031.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Actuate Therapeutics, Inc. (ACTU) reported warrant awards to Bios-affiliated funds and co-investment entities on October 28, 2026. The warrants are exercisable for common stock at $0.5325 per share, during a period running from October 28, 2026, through 5:00 P.M. New York time on October 28, 2031.
A footnote says the Bios Entities agreed to a two-year lock-up of issuer securities they beneficially owned, and Actuate agreed in consideration to issue warrants covering an aggregate of 3,000,000 common shares. The warrants were issued at the closing of Actuate’s public offering.
Insider Trade Summary
Grant/Award: 3,000,000 shares
Grant/Award
13 txns
Insider
BIOS Fund I, LP, Bios 2024 Co-Invest, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, Bios Clinical Opportunity Fund, LP, BIOS Fund I QP, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Fund II, LP
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 64,995 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 87,743 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 682,885 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 194,984 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 368,304 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 47,972 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 82,018 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 36,056 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 269,342 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 82,454 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 133,073 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 824,012 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 126,162 | $0.00 | $0.00 |
Holdings After Transaction:
Warrant (Right to Buy) — 64,995 contracts (Indirect, Directly held by Bios 2024 Co-Invest, LP);
Warrant (Right to Buy) — 87,743 contracts (Indirect, Directly held by Bios Actuate Co-Invest I, LP);
Warrant (Right to Buy) — 682,885 contracts (Indirect, Directly held by Bios Actuate Co-Invest II, LP);
Warrant (Right to Buy) — 194,984 contracts (Indirect, Directly held by Bios Actuate Co-Invest III, LP);
Warrant (Right to Buy) — 368,304 contracts (Indirect, Directly held by Bios Clinical Opportunity Fund, LP);
Warrant (Right to Buy) — 47,972 contracts (Indirect, Directly held by Bios Fund I QP, LP);
Warrant (Right to Buy) — 82,018 contracts (Indirect, Directly held by Bios Fund I, LP);
Warrant (Right to Buy) — 36,056 contracts (Indirect, Directly held by Bios Fund II NT, LP);
Warrant (Right to Buy) — 269,342 contracts (Indirect, Directly held by Bios Fund II QP, LP);
Warrant (Right to Buy) — 82,454 contracts (Indirect, Directly held by Bios Fund II, LP);
Warrant (Right to Buy) — 133,073 contracts (Indirect, Directly held by Bios Fund III NT, LP);
Warrant (Right to Buy) — 824,012 contracts (Indirect, Directly held by Bios Fund III QP, LP);
Warrant (Right to Buy) — 126,162 contracts (Indirect, Directly held by Bios Fund III, LP)
Footnotes (5)
- F1. Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.
- F2. A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.
- F3. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.
- F4. Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
- F5. The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
Key Figures
Aggregate warrant underlying shares: 3,000,000 common shares
Exercise price: $0.5325 per share
Lock-up term: Two years
+4 more
7 metrics
Aggregate warrant underlying shares
3,000,000 common shares
Warrants described for the Bios Entities
Exercise price
$0.5325 per share
Warrants for common stock
Lock-up term
Two years
Bios Entities’ issuer securities beneficially owned
Warrant underlying shares after transaction
824,012 shares
BIOS Fund III QP, LP
Warrant underlying shares after transaction
682,885 shares
BIOS Actuate Co-Invest II, LP
Warrant underlying shares after transaction
64,995 shares
Bios 2024 Co-Invest, LP
Expiration date
October 28, 2031
Warrants
Key Terms
Warrants, exercise price, Exercise Period, lock-up
4 terms
Warrants financial
"warrants to purchase an aggregate of 3,000,000 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"at an exercise price of $0.5325 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Exercise Period financial
"period ("Exercise Period") commencing on October 28, 2026"
The exercise period is the fixed span of time during which the holder of an option or warrant can turn that contract into shares by paying the agreed strike price. Like a coupon with an expiration date, it sets a deadline for claiming the underlying stock; after it ends the right expires and is lost. For investors, the length and timing of the exercise period affect when shares may be acquired, the flexibility to act, and the contract’s practical value.
lock-up financial
"a two-year lock-up of securities of the Issuer"
A lock-up is an agreement that prevents company insiders, early investors or employees from selling their shares for a set period after a public share offering. It matters to investors because it temporarily limits the number of shares available to trade—like a scheduled hold on extra inventory—and when that hold ends a large number of shares can enter the market, potentially putting downward pressure on the stock price and revealing insiders’ confidence in the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When can ACTU's Bios Entities warrants be exercised, and when do they expire?
The exercise period begins October 28, 2026, and terminates at 5:00 P.M. New York time on October 28, 2031. Warrants not exercised by the expiration date become void, and rights under the warrant agreement cease at the close of business on that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
